Kadmon initiates Phase Ib/IIa trial of KD019 and Trastuzumab to treat HER2+ breast cancer
US-based Kadmon has started a Phase Ib/IIa trial of KD019, an orally bioavailable small molecule kinase inhibitor of Src, HER2, EGFR and VEGFR2/KDR, in combination with trastuzumab (Herceptin) to treat HER2+ breast cancer metastasized to the brain.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Neurology | Pharmaceuticals